Palisade Bio Doses First Patient in Phase 2b Ulcerative Colitis Trial
Palisade Bio said the first patient has been dosed in its global ASCENTRA-UC study evaluating once-daily oral PALI-2108 for ulcerative colitis.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.